These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 2400958)

  • 1. IL-2: efficacy in renal cell carcinoma and overall safety profile.
    Louie A
    Cancer Invest; 1990; 8(2):315-6. PubMed ID: 2400958
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
    J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma.
    Pierce WC; Belldegrun A; Figlin RA
    Semin Oncol; 1995 Feb; 22(1):74-80. PubMed ID: 7855622
    [No Abstract]   [Full Text] [Related]  

  • 4. IL-2 therapy proves durable in renal cell melanoma patients.
    Oncology (Williston Park); 1991 Sep; 5(9):71. PubMed ID: 1835879
    [No Abstract]   [Full Text] [Related]  

  • 5. Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer.
    Koretz MJ; Lawson DH; York RM; Graham SD; Murray DR; Gillespie TM; Levitt D; Sell KM
    Arch Surg; 1991 Jul; 126(7):898-903. PubMed ID: 1854252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal cell carcinoma and interleukin-2: a review.
    Wagstaff J; Baars JW; Wolbink GJ; Hoekman K; Eerenberg-Belmer AJ; Hack CE
    Eur J Cancer; 1995; 31A(3):401-8. PubMed ID: 7540404
    [No Abstract]   [Full Text] [Related]  

  • 7. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose interleukin-2 in the therapy of metastatic renal-cell carcinoma.
    Parkinson DR; Sznol M
    Semin Oncol; 1995 Feb; 22(1):61-6. PubMed ID: 7855620
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma.
    Thompson JA; Bianco JA; Benyunes MC; Neubauer MA; Slattery JT; Fefer A
    Cancer Res; 1994 Jul; 54(13):3436-41. PubMed ID: 8012963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of cytokines in the therapy of renal cell carcinoma.
    Ebert T; Schmitz-Dräger BJ; Ackermann R
    Recent Results Cancer Res; 1993; 126():113-8. PubMed ID: 7681213
    [No Abstract]   [Full Text] [Related]  

  • 11. [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2].
    Nakano E; Iwasaki A; Seguchi T; Sugao H; Tada Y; Matsuda M; Sonoda T
    Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):395-404. PubMed ID: 2072602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma.
    Fleischmann JD; Kim B
    J Urol; 1991 May; 145(5):938-41. PubMed ID: 2016805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation].
    Nomura K; Fujioka T
    Nihon Hinyokika Gakkai Zasshi; 1993 May; 84(5):831-40. PubMed ID: 8320888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
    Fujioka T; Nomura K; Hasegawa M; Ishikura K; Kubo T
    Br J Urol; 1994 Jan; 73(1):23-31. PubMed ID: 8298895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.
    Parkinson DR; Fisher RI; Rayner AA; Paietta E; Margolin KA; Weiss GR; Mier JW; Sznol M; Gaynor ER; Bar MH
    J Clin Oncol; 1990 Oct; 8(10):1630-6. PubMed ID: 2213100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma.
    Palmer PA; Vinke J; Evers P; Pourreau C; Oskam R; Roest G; Vlems F; Becker L; Loriaux E; Franks CR
    Eur J Cancer; 1992; 28A(6-7):1038-44. PubMed ID: 1627369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The value of interferons, interleukin-2 and tumor necrosis factor in the therapy of renal cell cancer].
    Wirth M
    Urologe A; 1991 Mar; 30(2):77-80. PubMed ID: 1711729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells.
    Robertson CN; Linehan WM; Pass HI; Gomella LG; Haas GP; Berman A; Merino M; Rosenberg SA
    J Urol; 1990 Sep; 144(3):614-7; discussion 617-8. PubMed ID: 2201792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
    Thompson JA; Benyunes MC; Bianco JA; Fefer A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):46-51. PubMed ID: 8284692
    [No Abstract]   [Full Text] [Related]  

  • 20. [Study of adoptive immunotherapy with lymphokine-activated killer (LAK) cells and interleukin-2 for metastatic renal cell carcinoma. I. Generation of LAK cells by incubation in serum-free medium].
    Nomura K; Fujioka T
    Nihon Hinyokika Gakkai Zasshi; 1993 May; 84(5):822-30. PubMed ID: 8320887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.